A federal judge in Maryland has refused to end the lawsuit Terran Biosciences filed against Compass Pathways in August 2022, clearing the way for a trial. The court denied Compass's motion for summary judgment on Sept. 25, and the case is scheduled for trial in September 2027, according to Compass's latest quarterly report to the SEC. Terran, the University of Maryland, Baltimore and former UMB researcher Scott Thompson accuse Compass and two of its former officers and directors of misappropriating what the complaint calls "psilocybin trade secrets" from Thompson's university lab, under federal and Maryland law. They want unspecified damages and an order barring Compass from using or disclosing the information.
Compass's side: the company says it "strongly disputes the allegations," that the trade secret at issue "is not used" in its COMP360 psilocybin treatment, and that the claims are about publishing it, not putting it in a product. The fight has also been about missing evidence: in August, the court refused to sanction the plaintiffs over lab notebooks from Thompson's lab that no one can find, ruling Compass hadn't shown they went missing after the duty to preserve them began. The case is moving at the same time as the FDA reviews Compass's application to approve psilocybin. The lawsuit doesn't stop that review, but it remains a financial risk that Compass says it can't yet estimate. First flagged in Psychedelic Alpha's Bulletin #234.
Health Secretary Robert F. Kennedy Jr. and Veterans Affairs Secretary Doug Collins announced up to $4.9 million over five years on Nov. 12 to lay the groundwork for the first U.S. studies of ibogaine for veterans with PTSD. The money pays for manufacturing, dosing and study design, not for treating patients yet. Beond, a Texas-based company that says it has treated more than 3,000 people with ibogaine at its clinic in Mexico, will share data and treatment guidance. "For veterans living with PTSD, we owe them both urgency and the best science we can produce," Collins said. Kennedy said officials may also fund work on ibogaine for addiction. The same day, the National Institute of Mental Health posted a $20 million funding notice for a research network on fast-acting drugs such as ketamine, esketamine and psilocybin, with awards expected in summer 2027.
Why it's slow: ibogaine is still Schedule I and can cause dangerous irregular heart rhythms, so clinics monitor patients' hearts with emergency help on standby. Treatment in Mexico typically costs $10,000 to $20,000. The announcement follows President Trump's April executive order on psychedelic research, and comes days after the DEA proposed 57 times more ibogaine for research in 2027. Rep. Morgan Luttrell (R-TX), a retired Navy SEAL, is one of the lawmakers on record about his own ibogaine treatment in our People Series: Politicians. Reported by the AP's Matthew Perrone and Military.com's Katherine Plummer.
People with Parkinson's disease who took two doses of psilocybin had lower levels of inflammation in their blood afterward, and the drop was still there a month after the last dose, according to a research letter in JAMA Psychiatry on Oct. 21. The UCSF team, led by psychiatrist Ellen Bradley with first co-author D. Parker Kelley of Columbia University's Mitochondrial PsychoBiology group, gave 12 adults aged 40 to 75 with mild to moderate Parkinson's and mood symptoms a 10 mg dose and then a 25 mg dose about two weeks apart. Blood samples from 9 of them showed a combined inflammation score (built from IL-6, IL-8, TNF-alpha, interferon-gamma and CRP) significantly lower one day after each dose and 30 days after the second. A marker of mitochondrial stress, GDF-15, also fell the day after each dose, but was back to baseline by day 30. "This gives us an initial biological signal to investigate," Bradley told NPR's Will Stone.
What it can't tell us yet. There was no control group, everyone knew they were getting psilocybin, and only nine people gave blood. The authors say placebo effects, regression to the mean, and changes in stress or sleep could explain some of the shift, and that the blood markers don't directly show what's happening to mitochondria in the brain. It doesn't show that psilocybin treats inflammation or Parkinson's, and it says nothing about microdosing. LSU pharmacologist Charles Nichols, who wasn't involved, called it "really exciting"; the next step is a controlled trial with longer follow-up.
Delix Therapeutics raised an oversubscribed $100 million Series C on Nov. 9, co-led by Johnson & Johnson's venture arm (JJDC) and SV Health Investors' Dementia Discovery Fund. The money funds zalsupindole, a pill designed to trigger the same brain rewiring as psychedelics (neuroplasticity) without hallucinations, so patients could take it at home instead of in a supervised all-day session. Delix plans to start a placebo-controlled Phase 2b trial in major depression in the first half of 2027, with at-home dosing the FDA has already cleared.
The evidence so far is early. In a small Phase 1b study of 18 adults with recurrent depression, scores reportedly fell by about half within a week, and the effect held through day 36. There was no placebo group, so those numbers can't yet separate the drug from expectation. The bigger question is the one the whole field is watching: whether a psychedelic works as well without the psychedelic experience. Delix also has early-stage, no-trip drugs based on ibogaine, 5-MeO-DMT and LSD.
Delix grew out of the UC Davis lab of chemist David E. Olson, who coined the term "psychoplastogen." J&J already sells Spravato, the esketamine nasal spray for depression. For how these "analog" drugs work and how the law treats them, see our encyclopedia entry. Reported by BioSpace's Tristan Manalac.
A Brussels psychiatric hospital group is seeking permission to give psilocybin to people with treatment-resistant depression outside a clinical trial, which would be a first for Belgium. The nonprofit Epsylon would run the compassionate use program under psychiatrist Dr. Daniel Souery, with psilocybin supplied by Filament Health, a subsidiary of Canada's Rhelion Life Sciences (formerly Red Light Holland), the companies announced. Filament's drug, PEX010, is psilocybin extracted from whole mushrooms in standardized 1mg, 5mg and 25mg doses. The program still needs approval from Belgium's medicines agency (FAMHP), an ethics committee and import permits; no start date or patient numbers have been given. Psychedelic Society Belgium, an advocacy group that says Belgium's 1921 drug law is overdue for "a framework of compassion," backs the plan.
The model: Germany already runs the EU's first psilocybin compassionate use program, using the same Filament drug, at the Central Institute of Mental Health in Mannheim since 2025. Belgium would be the second EU country, while psilocybin elsewhere in the bloc remains trial-only. In the U.S., two psilocybin applications are now under FDA review. See Belgium on our global legal map and Filament's programs on our trials tracker.
University of Florida researchers have found the first mushroom known to produce both psilocybin and amatoxins, the liver-destroying compounds in death cap mushrooms. The tiny Galerina indica, which they nicknamed the "dark magic mushroom," turned up on a rotting palm trunk in a central Florida wetland. Its flesh bruised blue, a common sign of psilocybin, which is what prompted the testing. The study, published Wednesday in Current Biology, also identified a new amatoxin and a second new Galerina species that makes only psilocybin. The researchers think the mushroom picked up its psilocybin genes from an unrelated fungus millions of years ago. "Do not eat this mushroom!" lead author Andrew Kunik told Gizmodo's Ed Cara. Science News' Tina Hesman Saey quoted mycologist Anne Pringle of the University of Wisconsin–Madison, who wasn't involved, on the question people ask when they find a mushroom: "Can I eat it?" She said she's always uncomfortable with it, and "this paper confirms that, in fact, you should be uncomfortable." The lesson for foragers: blue bruising doesn't mean a mushroom is safe. Small brown Galerina mushrooms are hard to tell apart, and several are deadly.
If someone may have eaten a wild mushroom: call Poison Control (1-800-222-1222 in the U.S.) right away, even if they feel fine. Amatoxin symptoms often don't start for six hours or more, by which point liver damage may be under way. Feeling the effects of psilocybin doesn't rule out amatoxin. For the psychological side, see our guide to what a "bad trip" actually is.
Dr. Ben Malcolm, a pharmacist who specializes in psychedelic drug interactions, is flagging a risk that rarely comes up in MDMA discussions: men with an enlarged prostate (benign prostatic hyperplasia, or BPH) may have trouble urinating after a dose. MDMA strongly boosts norepinephrine, which tightens the muscle where the bladder meets the prostate, the opposite of what prostate drugs like tamsulosin (Flomax) do. Emergency doctors have published case reports of MDMA-linked urinary retention since 1995, in the BMJ and BJU International, and a 2008 case described lasting bladder problems after heavy, chronic use. Malcolm is clear about the limits. He calls the BPH link "an extrapolation" and says "this is not a contraindication," since no study has looked at men with BPH taking MDMA. His advice: empty the bladder before dosing and every couple of hours after, see a urologist first if you already have trouble urinating, and get care if you can't go for six to eight hours despite the urge. He also suggests clinicians ask about urinary symptoms, which patients rarely volunteer, and consider keeping men on their prostate medication during sessions.
Why it matters now: Resilient Pharmaceuticals' MDMA drug, Rysanso, is under FDA review for PTSD, and many of the people it would treat, including older veterans, are in the age group most likely to have an enlarged prostate. Malcolm sells consulting and paid memberships through Spirit Pharmacist; this post isn't tied to a product. This is journalism, not medical advice, and MDMA is not FDA-approved for any use.
The Drug Enforcement Administration has proposed sharply higher 2027 production limits for several psychedelics used in research, Marijuana Moment's Tom Angell reports. The biggest jump is for ibogaine: from 210 grams this year to 12,002 grams, about 57 times more. MDMA would rise from 12,000 to 33,296 grams, psilocybin from 50,000 to 60,000 grams, and psilocin, the compound psilocybin turns into in the body, from 80,000 to 93,600 grams.
The DEA says the MDMA and ibogaine increases are for research and clinical trials in conditions including PTSD and depression, and that they "align with" President Trump's April executive order on psychedelic research. These quotas cap how much of each Schedule I drug can legally be manufactured in the U.S. each year, so they set a ceiling on how many trials can run. The notice is due in the Federal Register this week, followed by a 30-day public comment period.
For ibogaine, it's a sign of how fast the compound has moved from a niche to a research priority, with state-funded programs in Texas and Arizona and private money such as Sergey Brin's backing of the startup Soneira, covered in this week's People Series. Our ibogaine deep dive covers the cardiac risks those trials have to manage. Active ibogaine and MDMA trials are on our trials tracker.
Most psychedelic research happens in clinics, with screened patients and a controlled dose. A new UCSF study called CANOPY goes the other way. It will follow up to 3,000 people around the world who already plan to use a psychedelic, at home, at a retreat or somewhere else, and track them from before the experience to six months after. The researchers don't supply drugs or choose what people take. The study covers psilocybin, LSD, ayahuasca, ibogaine, MDMA and ketamine.
Most of it runs remotely through questionnaires. Participants who can travel to UCSF also get brain imaging and EEG, give blood and saliva samples, and wear tracking devices. "CANOPY gives us an opportunity to bring scientific rigor to these experiences at a scale we haven't had before," said Robin Carhart-Harris, the UCSF neurology professor who leads it. Funding comes from ARPA-H, the federal health research agency: up to $1.4 million for CANOPY, part of up to $8.5 million across three UCSF psychedelic projects. One, co-led by Jennifer Mitchell, looks at how set and setting shape a trip. Another, with Lorenzo Pasquini, studies older adults with early signs linked to Alzheimer's.
It's the research version of what the Fireside help line's 25,000 calls showed: most psychedelic use is happening outside clinics, and almost nothing is known about how it goes. UCSF says it does not provide psychedelics or direct people to obtain them.
Compass Pathways said Monday it has completed its new drug application for COMP360, its synthetic psilocybin, in treatment-resistant depression. It said "two weeks" on Nov. 3 and finished in six days. The application covers two Phase 3 trials and a Phase 2b study with more than 1,000 participants combined. CEO Kabir Nath said Compass is "focused on delivering COMP360 to patients as quickly as possible, subject to FDA approval," and the company is targeting a launch in the first half of 2027.
Three at once: The FDA now has three psychedelic applications in front of it: Compass's psilocybin for treatment-resistant depression, Usona Institute's psilocybin for major depression (filed Nov. 2), and Resilient Pharmaceuticals' MDMA for PTSD, resubmitted this summer, per Psychedelic Alpha. Compass and Usona both hold National Priority Vouchers, which aim to cut review from 10–12 months to one to two. BioSpace's Heather McKenzie reports that Stifel analysts expect approval "within the 1Q27 timeframe (if not earlier)."
After approval: psilocybin is still Schedule I. The DEA has to reschedule it, and each state has its own step. We mapped which states switch on automatically in The Day After Approval. ICER's comment period on its cost review of COMP360 also closes Tuesday, Nov. 10 at 5pm ET. Both psilocybin programs are on our trials tracker, and the companies are on our intelligence hub.
Definium Therapeutics, the company formerly called MindMed, reported third-quarter results after the market closed on Monday. It answered one of the questions we were watching for: it says it is "on track" to file a new drug application for DT120, its LSD tablet, in the first half of 2027. It didn't answer the other. The release doesn't say whether the first filing will be for generalized anxiety disorder, where two Phase 3 trials (Voyage and Panorama) came back positive, or for major depression, where one Phase 3 (Emerge) was positive and a second (Ascend, now about 165 participants) won't read out until 2027.
The money: Definium had about $1.05 billion in cash and investments on Sept. 30, up from $411.6 million at the end of 2025, and says that funds the company into 2030. The quarterly net loss was $51.0 million. Spending is rising on the business side: general and administrative costs climbed to $26.1 million from $14.7 million a year ago, which the company put down partly to government affairs and commercial preparation. It plans a first "Commercial Day" for investors in the first half of 2027 to lay out its launch strategy.
Beyond LSD: Definium also shared first results for DT402, a single mirror-image form of MDMA, in autism. The open-label study gave one 200 mg dose to five adults. The company calls the results "positive initial," citing less rigidity and anxiety and more social engagement, but the endpoints were exploratory and the study wasn't designed to draw statistical conclusions. A multiple-dose study is planned for 2027, as is Haven, a roughly 200-person Phase 3 of DT120 in PTSD.
CEO Rob Barrow said the trial results show "consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD." DT120 is not FDA-approved for any use. The full program is on our trials tracker, and Definium is on our intelligence hub.
The Fireside Project runs a free, volunteer-staffed phone and text line for people in the middle of a psychedelic experience or working through one afterward. In a study published in Science Advances, its team analyzed 25,419 conversations from April 2021 to February 2026. PsyPost's Eric W. Dolan covered the findings.
Psilocybin came up in about 60% of the contacts that named a substance, followed by LSD (14%), cannabis (13%) and ketamine (8%). About 40% of callers reached out during an experience and 32% afterward, for integration. Distress ran about 47% during an experience and 36% afterward, and once the researchers accounted for that timing, the differences between drugs were not statistically significant. "When people struggle with psychedelics, timing matters more than the substance," said Joshua White, Fireside's founder.
Two-thirds of callers were alone. Fewer than 1% of contacts were escalated to 911 or 988. Forty-three conversations, or 0.2%, involved reports of abuse by a facilitator, mostly in ceremonial settings. Those accounts were unverified.
The limits: Fireside funded and ran the study, so the 76% of surveyed callers who said they felt supported is a self-assessment. The data only covers people who chose to call, and the study can't show whether the line prevented harm. "Our distress rates describe our callers, not the population-level risk of any drug," White said. For more on what a bad trip is and how harm reduction works, see our encyclopedia.
The next two weeks will decide a lot. Here's what's on our calendar, and one study from this week.
Nov 9: Definium reports Q3 (4:30pm ET). Shares have roughly doubled in the past month, and this is the company's first call since. The trial data is already out. Two Phase 3 trials of DT120 for generalized anxiety came back positive, as did a depression trial. What's missing is a filing date. We'll be listening for when Definium plans to submit its NDA and in which indication it goes first. The second depression trial, Ascend, doesn't read out until 2027.
Nov 11: Compass at the Stifel healthcare conference. CEO Kabir Nath gets a second chance to answer the question he declined on the Nov 3 call: what a two-company psilocybin market looks like now that Usona has filed. Compass's cash, which it says lasts into 2028, means it can wait for approval without raising money first.
Around Nov 17: Compass's two-week filing window closes. On Nov 3, Nath said the rolling NDA for COMP360 would be complete "in the next two weeks." Once it's in, the company's National Priority Voucher could shrink the FDA's review to one to two months. That would put both psilocybin applications, Compass for treatment-resistant depression and Usona for major depression, in front of the FDA at the same time. Both programs are on our trials tracker.
Nov 20: FDA's ibogaine comment deadline. This is the last day to respond to the FDA's request for input on how early ibogaine trials should be designed. The agency named opioid use disorder and PTSD as priority populations and flagged heart-rhythm and neurotoxicity risks. It has said it won't consider comments on legalization or scheduling. Texas, now under Gov.-elect Gina Hinojosa, and Arizona run state-funded ibogaine trials, and both will be watching what comes back.
Further out: who writes the FDA's next funding bill. With Democrats taking the Senate, Bernie Sanders is expected to lead the Senate health committee, RAPS reports. That's the committee Bill Cassidy chaired. It shapes the reauthorization of FDA user fees, the industry money that pays for drug reviews. The law expires Sept. 30, 2027, and the FDA's recommendations are due to Congress by Jan. 15. In past reauthorization cycles, Sanders was often the lone vote against it in committee. Our midterms breakdown covers the rest of the new map.
On our desk: a new study from the University of Melbourne and the Florey Institute, covered by Eric W. Dolan at PsyPost. Researchers James Gattuso, Anthony Hannan and Thibault Renoir gave mice bred to model schizophrenia one dose of psilocybin. In females, it restored sensory filtering for about nine days. The study is small, uses one genetic strain, and the effect appeared in only one sex. It's exactly the kind of single-lab, lasting-effect result that this week's five-lab replication suggests we should hold loosely. The lead author warns against self-treatment. People with schizophrenia or a family history of psychosis are typically excluded from psychedelic trials for safety reasons.
Compass Pathways closed the third quarter with $444.0 million in cash, up from $149.6 million at the end of 2025, and now says that is enough to fund operations into 2028. That carries the company past its targeted launch rather than leaving it racing to one. The quarter's books, under CFO Teri Loxam, also showed $51.0 million in debt and selling, general and administrative spending of $33.0 million, which the company says is rising as it builds out commercial launch preparation. A $40.8 million non-cash gain on its warrants shrank the headline quarterly loss to $9.8 million. Compass warned that this line will swing with the share price.
The bigger news was timing. On the Nov. 3 call, CEO Kabir Nath said, "We will complete our rolling NDA submission in the next two weeks," for COMP360 synthetic psilocybin in treatment-resistant depression, with launch prep aimed at the first half of 2027 if the FDA approves. The company's National Priority Voucher could shrink the review itself to one or two months. Asked by Stifel's Paul Matteis about a two-player psilocybin market, Nath declined to discuss Usona, which filed its own psilocybin NDA for major depression days earlier, saying only that Compass's indication is "TRD, and that is fundamental to the value." Psychedelic Alpha's Josh Hardman covered the call, and STAT's Elaine Chen is framing it as a straight race for the first psychedelic approval. Both programs' trial histories sit side by side on our trials tracker, and Compass's investor calendar continues at a Stifel fireside chat on Nov. 11.
Five labs across UC Berkeley, UCSF and Stanford ran the same psilocybin experiments on mice in parallel, using matched protocols, and published the results together in Nature Neuroscience this week. The study design was proposed by Stanford's Robert Malenka. The labs were led by Stephan Lammel and Andrea Gomez at Berkeley, Vikaas Sohal and Mazen Kheirbek at UCSF, and Boris Heifets at Stanford. The acute effects replicated everywhere. At 2 mg/kg, every lab saw the head twitch that researchers use as a marker of psychedelic activity in mice. Every lab also saw a spike in anxiety and avoidance 10 minutes after the dose, along with reduced fear expression.
The effects that drive much of the therapeutic interest did not replicate. Twenty-four hours after a single dose, the labs found no consistent reduction in anxiety- or depression-like behavior, no change in fear or social behavior, and no sign that psilocybin reopens a "critical period" for social reward learning in adult mice, a widely cited earlier finding. Two labs did see an effect on one of two standard antidepressant assays, which the authors attribute more to the assay's limits than to the drug. Co-first author Odilia Lu, a Berkeley doctoral student, called the lasting effects "modest, if anything," and cautioned that mouse tasks "just can't capture the really complicated human." Sohal put the stakes plainly: "if the hype around psychedelics outruns the science, there will be adverse outcomes."
This is a mouse study, and it doesn't overturn the human Phase 3 data now in front of the FDA. It does weaken the animal evidence often cited as the mechanism, and it shows that single-lab results deserve less weight than they get. It lands a week after a JAMA Network Open review found media coverage of psilocybin routinely outpaces the evidence. Robert Sanders wrote it up for Berkeley News, and STAT's Readout also covered it. Our intelligence hub tracks how the research base behind each compound is holding up.
Psychedelic Alpha's Josh Hardman and Noah Smith report that the nonprofit Usona Institute has completed a new drug application with the FDA for its psilocybin candidate for major depressive disorder — reporting the outlet says it understands independently, since Usona itself declined to comment. That makes it the second psychedelic NDA currently before the agency, after Resilient Pharmaceuticals (formerly Lykos) refiled its MDMA-for-PTSD application this past summer.
Usona holds a Commissioner's National Priority Voucher, which the outlet says aims for a decision within roughly two months — pointing to a possible FDA call in late 2026 or very early 2027 — on top of the Breakthrough Therapy Designation and rolling review it already had. Per Psychedelic Alpha's sourcing, Usona is working with FDA on the agency's questions and on designing a risk evaluation and mitigation strategy, and the FDA has already inspected several Usona sites, including its Wisconsin headquarters.
Compass Pathways' COMP360, further along in some respects, is the other half of this race — Compass has guided that it will file its own treatment-resistant-depression NDA this quarter, and the outlet reports FDA site inspections of Compass began in September. A Compass quarterly update was due the day after this story ran. Psychedelic Alpha calls the two companies "neck and neck," with Usona holding "a slight edge" on filing timing for now, while noting Compass may still have advantages in the commercial steps between approval and launch. Our own trials tracker keeps both programs' trial-stage history in one place as this plays out.
A guest essay in today's New York Times, by Dr. Daniela J. Lamas — a pulmonary and critical care physician at Brigham and Women's Hospital — argues that psychedelic research almost never reaches the patients she treats: people dying in the hospital, often in the I.C.U. The trials that have found psilocybin eases existential distress in people with life-threatening cancer, dating back to landmark 2016 studies, enroll patients well enough to sit through hours of preparatory therapy, a supervised multi-hour session, and weeks of follow-up. Someone actively dying in a hospital bed usually can't clear that bar, and Lamas's case is that regulators building the delivery framework for these drugs should design for that patient too, not just the one stable enough to travel to a clinic.
The regulatory backdrop she's writing into is real and recent: the FDA finalized its guidance on psychedelic drug clinical trials in July 2026, and followed it in September with a public hearing — "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," held Sept. 14 — gathering input on exactly the delivery questions Lamas raises, from provider credentialing to patient monitoring. She notes the FDA could decide on psilocybin for treatment-resistant depression as soon as early 2027, which lines up with outside estimates we've seen elsewhere tying a possible first approval to roughly the same window.
Lamas is careful about the limits of the case she's making. She flags, unprompted, that psychedelic trials are nearly impossible to blind — patients who know they got something they've read could change their life may feel better partly because of that belief, or because of the hours of dedicated therapy that come with it, independent of the drug — and that there are documented accounts of harm, including persistent anxiety, especially outside research settings. What's actually available to her today is ketamine, already approved for sedation and pain control, which she's seen colleagues like Dr. Zachary Sager at Dana-Farber use off-label for existential distress with some patients, by his account to her — a single case of a 78-year-old cancer patient whose wish to hasten death resolved for nearly a week, that she's explicit is not proof of anything, since trials of ketamine for this use have had mixed results.
Worth being precise about what this is: a practicing physician's opinion essay, not a trial result, and nothing here is evidence that psilocybin or ketamine treats dying patients' distress outside a research setting. It's a useful read anyway for naming a real gap — between who psychedelic trials are designed to enroll and who's actually sitting in the hospital beds these drugs are increasingly being discussed for.
Psychedelic Alpha's Noah Smith and Josh Hardman report that the FDA has approved NRx Pharmaceuticals' generic, preservative-free ketamine, branded KETAFREE — about three months later than the company expected, and on-label only for anesthesia, the same indication as the branded product it copies, Ketalar. NRx developed it with Nephron Pharmaceuticals, which handles fill-and-finish manufacturing in South Carolina.
The approval is step one of a two-part strategy the outlet has been tracking since early 2025. Step two, still pending, is a citizen petition NRx filed with the FDA in September 2025 asking it to ban ketamine products that use the preservative benzethonium chloride (BZT) — which would force most of the rest of the U.S. ketamine market, including Ketalar as currently made, off the shelf. Psychedelic Alpha's own reporting is skeptical of the safety case behind that ask: it finds NRx's supporting toxicology report models anesthesia and ICU-level dosing rather than psychiatric dosing, contains internal inconsistencies, and leaves out a study that found BZT didn't reach mice's brains. The outlet also notes NRx has had to narrow an earlier "first preservative-free ketamine" claim, since Baxter received FDA approval for its own preservative-free ketamine syringe in September 2025 and again in August 2026.
Per the outlet, Chairman and Chief Scientist Jonathan Javitt says NRx will price KETAFREE in line with the market and holds no exclusivity on it. The approval doesn't touch the psychiatric side of the ketamine market: Spravato remains the only ketamine-derived product approved for a psychiatric indication, and NRx's separate push for an on-label psychiatric ketamine product, NRX-100, is a distinct program still working through the FDA. We looked at how thin the commercial patent protection around ketamine actually is in our deep dive on the ketamine patent gap — this is a live example of a generic challenger trying to use a citizen petition, not a patent fight, to clear the field.
Psychedelic Alpha's own writeup of the Psychedelic Healthcare Forum it co-hosted in New York this month — the same event behind our coverage of its federal-policy panel — turns to the money side. One session, "A Conversation with Carole Ho," is framed under the subheading "5-MeO-DMT Fits the Spravato Model" — Eli Lilly's head of neuroscience R&D drawing a direct comparison to ketamine's existing FDA-approved depression franchise, though the outlet's own reporting on what she said beyond that framing sits behind its paid tier.
The fuller, publicly readable section covers an investor panel, "Courting Capital for Psychedelic Medicine," moderated by Bloomberg's Madison Muller. Ritu Baral of TD Cowen said clinical trial risk has eased and FDA guidance has gotten clearer, with efficacy concerns being "knocked down one by one" — but reimbursement and operational questions remain. She called pharma "cash rich and pipeline poor," flagging PTSD and depressive disorders as the biggest opportunities. Connor Williams of RTW Investments, which backs Compass Pathways, said the field has produced "20 SSRIs, 40 dopaminergic antipsychotics, and just two or three pharma acquisitions of psychedelics" so far. Palo Santo's Edny Inui said patent concerns have largely faded and that first movers with novel formulations attract large-pharma interest — pointing to Johnson & Johnson's role driving Spravato adoption, and naming Bristol Myers Squibb as a possible acquirer next.
Some additional coverage worth flagging, on the supply side of the same industry: ibogaine's raw material. Journalist and ethnobotanist Molly Helfend's investigation for Mongabay — reported from Libreville in July, published Aug 26, 2026, and republished in adapted form by DoubleBlind on Oct 30 — covers Gabon's Decree No. 0239/PR/MJSRCAVA, which sets up a national framework governing access to iboga, its derivatives, and the traditional knowledge around it. As of 2025 reporting, only one company held a Gabonese export license; Helfend's reporting asks whether that arrangement is actually delivering benefits back to the communities it draws from as the global ibogaine boom — the same boom driving the political and pharma-investor interest covered above — accelerates demand for the plant.
A systematic review in JAMA Network Open (Kim Madden, lead author, with Breanne Flood, Imad Kashir, Rayan Ahmad, Hiba Ali, Rotem Petranker, James MacKillop, and senior author Anthony Adili) compared 70 psilocybin trial publications (2014–2024) against 172 news articles covering them (2014–2025), reported by PsyPost's Eric W. Dolan on Oct 27.
The gap isn't really about whether psilocybin "works" — 70% of trials concluded benefit on their primary outcome, and 73% of news articles made a positive claim, which looks close. It's in the framing and the silences around that number. Trial authors routinely flagged limitations and small samples (93% of the 70 papers had fewer than 100 participants); news coverage largely didn't, with 71% of articles striking a favorable tone outright. Coverage also extrapolated well past what's been tested: PTSD appeared in 43% of articles despite zero eligible trials testing it, anxiety in 42% of articles against just 4 trials, and anorexia/eating disorders in 10% of articles against a single trial. Safety got the least attention on either side, but the asymmetry held: 44% of trials reported safety outcomes versus just 30% of news articles mentioning adverse effects at all, and 83% of articles never mentioned dosing.
Adili's own framing to PsyPost: "there is a disconnect between media publications and the hard science," and "media articles may bias positive results without discussing safety concerns." It's a fair prompt for any outlet writing about this compound, including ours — our own encyclopedia entry and trials tracker are the two places we try to keep the trial-stage caveats attached to any psilocybin claim we make.
Psychedelic Alpha's Ryan Khan reported from Estonia's first international psychedelic-therapy conference, TAIP 2026 in Tallinn, with a five-country snapshot of where European policy actually stands — not announcements, implementation.
Norway is the furthest along: after a campaign led by Dr. Lowan Stewart, its health technology body backed national reimbursement for generic ketamine therapy for treatment-resistant depression in 2025 — covering the full treatment package, therapy included, not just the drug. (Johnson & Johnson, which sells the patented esketamine version at up to €207 a dose against generic ketamine's roughly €6, has publicly opposed the model.) In August 2026, Norway became the second country after France to approve ketamine for acute suicidal crisis regardless of diagnosis. At TAIP, Norway's program was presented as the model Estonia's own advocacy group wants to replicate within five years.
In the UK, Imperial College London's Dr. David Erritzoe presented pilot data from St. Charles Hospital on CIM-KeT, a ketamine-assisted psychotherapy protocol now training clinicians across 17 NHS trusts: an 89% reliable improvement rate against 45% for standard NHS talking therapy — pilot numbers Erritzoe himself called preliminary, not a published trial result. Norway sent its own clinicians to the first CIM-KeT training session, Oct 3–4.
Germany's compassionate-use psilocybin program, running since July 2025 at two sites, is still narrow: after regulators questioned a 30mg dosing error, doses are now capped at 25mg, and the program only admitted its first statutory-insurance patient in early October. Prof. Gerhard Gründer predicted no licensed psychedelic in Europe for at least a couple more years, citing the field's lack of a standard-of-care comparator trial. Switzerland, running compassionate exceptions since 2014, logged 775 patients across 15 sites in 2025 — mostly psilocybin, with MDMA and LSD behind it — though speaker Helena Aicher was explicit that patients have no legal right to access; it's capacity-limited, case by case. See how each country's legal status compares on our tracker.
Psychedelic Alpha reported from the Psychedelic Healthcare Forum in New York, moderated by POLITICO's Deputy Health Care Editor Erin Schumaker, where the Veterans Health Administration gave its clearest numbers yet on how it plans to roll out psychedelic therapy.
Andrew Gradison, a Senior Advisor to the VA, said the agency has chosen ten sites to go first — selected for having clinical trial experience with psychedelics already, though he wouldn't name them — after presenting a phased implementation plan to VA Secretary Doug Collins three weeks before the forum. The scale of what those ten sites are up against: the VA covers roughly 9 million veterans, 6.4 million of whom receive regular care, and about 2.1 million of those carry a diagnosis of PTSD, major depressive disorder, or treatment-resistant depression — all conditions with active VA and Pentagon psychedelic research behind them already.
Gradison said that if a therapy becomes available in January or February of next year, the VA would start treating patients immediately, but was candid about the ceiling: "I think, to manage expectations, it'll be a challenge in the first year to treat four digits' worth of patients," he said. "Demand will exceed our ability to supply these therapies." Group therapy formats came up as one of the few realistic ways to expand capacity without expanding staff. The same forum also covered ibogaine's separate, slower regulatory path and FDA risk-mitigation (REMS) requirements for psychedelics broadly — both still open questions the VA's own timeline depends on.
Oregon's psilocybin services program was designed to pay for itself through license fees rather than the state's General Fund — but as of earlier this year, it wasn't closing the gap. The Oregon Health Authority's fix, still in a draft rule as of Sept 1, would have doubled annual license fees: $2,000 to $4,000 for solo facilitators, $10,000 to $20,000 for service centers and manufacturers, while eliminating the reduced $1,000 rate for veterans and low-income applicants entirely. Lucid News' Joseph Gallivan reports that after weeks of organized public comment, OHA reversed course on Sept 22 and shelved the increases, crediting advisory-body and public input in its statement; a spokesperson declined to elaborate further.
The reversal matters beyond Oregon's borders because it's a live test of a funding model other states are watching: we've tracked the $8.7 million in regulatory infrastructure Oregon's Measure 109 program has required, and this was the state's attempt to make licensees cover that cost directly rather than taxpayers. Andreas Met, co-founder of Satya Therapeutics, called the proposed hikes "deeply flawed" and said the underlying funding problem isn't solved — his Psilocybin Alliance now plans to lobby the legislature for a more sustainable model. Taylor West of Healing Advocacy noted the program has already served more than 24,000 people and argued it should be folded into the state's broader mental health system rather than funded fee-by-fee. The affordability stakes are real: this therapy isn't covered by insurance, so the people using Oregon's program already pay out of pocket, and operators warned that passing a fee hike through to patients would push the service further out of reach for exactly the lower-income users the reduced rate exists to protect.
Matt Zorn joined HHS as Deputy General Counsel in May 2025 and is now, per Marijuana Moment's reporting, informally known inside the department as its "psychedelics czar." The irony: he got there by suing the government. In 2023 he forced HHS to release its unredacted scientific recommendation to reschedule cannabis via a FOIA suit, and he represented terminally ill patients seeking psilocybin access under Right to Try laws against the DEA — a case the courts ultimately decided in the DEA's favor. He was also involved in the legal challenge to the DEA's proposed Schedule I listing of five psychedelic tryptamines we covered this month — the same agency he's now, as an HHS official, working alongside rather than against.
Interviewed by Psychedelic Alpha editor Josh Hardman at The Psychedelic Healthcare Forum in New York, Zorn described the April 2026 psychedelics executive order as reflecting a willingness to "question our status quo assumptions," and pushed back on any sense that HHS is moving chaotically: "very orderly," he said, crediting the Secretary with hiring him partly because of his track record suing the department. He framed psychedelics as "a tool that can go in the toolbox" for the mental health crisis — not the only solution — and said officials across party lines want to move the issue forward. Asked directly whether an approved psilocybin drug could eventually undercut the logic of keeping the underlying compound in Schedule I, he declined to answer, citing his government role.
The interview's stated focus — his views on ibogaine specifically and the mechanics of Right to Try — runs behind Psychedelic Alpha's paywall; what's above is what's publicly available. We'll follow up if more surfaces.
"Stacey Dooley: Down the K Hole," a BBC Three documentary filmed over five months at the Acorn Recovery rehab unit in Stockport, puts a human face on the ketamine harm numbers we've covered elsewhere this month. The Times' Carol Midgley, reviewing it at four stars, described 19-year-old patients wearing sanitary briefs because their bladders could no longer hold urine, and one young man, Josh, whose bladder and kidneys stopped functioning after a decade of daily use — surgeons drained his kidneys into an external bag and told him the bladder itself would need rebuilding from his small intestine. He used ketamine again after leaving hospital.
The mechanism is specific, not generic drug damage: ketamine is cleared through the kidneys into the bladder, and at the doses recreational users described — far above the 30–150mg clinical range for Spravato-style depression treatment — repeated exposure inflames and ulcerates the bladder lining until the muscle wall fibroses and the organ shrinks, sometimes to a holding capacity of a few tablespoons. That's ketamine-induced cystitis, a well-documented clinical entity, not a dramatized side effect. Midgley's one real criticism: no urologist on camera to walk through why this happens, which is the gap we're filling here.
The film isn't only grim. Two other patients, Liam and Phoebe, met in treatment, stayed sober, and are now expecting a baby together — the same drug, the same unit, a different ending. This is culture coverage of a documentary review, not medical advice.
A controlled trial out of Imperial College London's Centre for Psychedelic Research, led by Taylor Lyons with senior author Robin Carhart-Harris — whose REBUS model we've referenced before — gave 28 psychedelic-naive adults a 1mg placebo and a 25mg psilocybin dose a month apart, tracking both with EEG and MRI. The high dose produced a sharp spike in brain entropy — more irregular, less predictable electrical activity, peaking 1–2 hours after dosing, alongside a drop in alpha-wave activity — a real-time signature of the default mode network loosening its usual grip.
What makes this more than a brain-imaging curiosity: participants who showed the biggest entropy spikes also reported the largest gains the next day — psychological insight scores rose roughly 51 points on a 0–100 scale, well-being improved 4.7 points on a 14–70 scale versus placebo, and cognitive flexibility measurably improved a month out. Entropy wasn't just correlated with the trip; it tracked with what the trip left behind.
The caveats are real and the authors are upfront about them: dosing order was fixed (placebo always first), the main hypotheses weren't pre-registered, and statistical corrections were applied within outcome measures but not across all of them — exploratory work, not confirmed science. Katrin Preller, an outside researcher not involved in the study, told PsyPost it lacks "rigorous protection against false positive findings" and needs replication in a larger, properly randomized design before anyone treats entropy as a validated predictor of who benefits from psilocybin.
"The dose makes the poison," The New York Times' Andrew Jacobs wrote this week, revisiting the pharmacology question at the center of the Cornell lawsuit we covered when New York's attorney general took over the case. Named specialists put real numbers on just how wide ketamine's effective range actually is: a clinical IV or IM dose for depression runs roughly 30–150mg, delivered slowly over 40–60 minutes with vitals monitored throughout, while recreational users snorting the powdered form "sometimes... more than 1,000 milligrams at once," per Dr. Sandhya Prashad, president of the American Society of Ketamine Physicians, Psychotherapists and Practitioners — up to ten times the clinical dose, measured out with none of a clinic's precision.
That gap is what produces a K-hole, a state of near-catatonic dissociation that, per Prashad, even a modest dose can trigger in a first-time user, leaving someone "awake but disconnected" for up to 45 minutes. Dr. Dave Rabin, a ketamine-assisted-therapy psychiatrist, drew the same line our own coverage did — it's the dose, not the drug itself, that separates therapeutic use from dangerous use: "Too much ketamine and a person's judgment is impaired and they don't have the agency to assert themselves," he told the Times, while also warning that cases like this risk getting "powerful therapeutic tools like ketamine" miscategorized as pure drugs of abuse.
As with our earlier coverage, this is pharmacology and harm-reduction reporting, not legal commentary on an active, disputed case — no charges have been filed, and the accused deny wrongdoing. Full reporting, including testimony from the woman identified in the lawsuit as Jane Doe, at The New York Times.
Two days after the FDA opened its public comment docket on ibogaine trial design — which we covered here — Chemical & Engineering News flagged a separate, quieter milestone: the FDA has cleared an IND application for noribogaine hydrochloride, an ibogaine derivative designed to retain its potential as an addiction treatment without the psychoactive effects, sponsored by DemeRx NB for a Phase 1 alcohol use disorder trial. It's the first time the agency has allowed any US clinical study of an ibogaine-related compound — notable given DemeRx's own ibogaine HCl program, covered in our patent deep dive, stalled after a cardiac signal in a Phase 1 participant.
The momentum isn't just federal. C&EN notes Arizona, California, and Indiana have passed legislation supporting ibogaine research, and Texas committed $50 million to study the drug last year after a campaign led by former governor Rick Perry. "This is the most important regulatory signal ibogaine has received in decades," Tom Feegel, CEO of the Mexico-based ibogaine clinic Beond, told Reuters. Ibogaine itself remains Schedule I, with "no currently accepted medical use" in the DEA's own classification — a derivative clearing even a Phase 1 bar doesn't change that, and FDA drug center director Michael Davis was explicit about why the caution stays high: "there are important scientific questions as well as serious safety concerns." Ibogaine's cardiac risk, not its hallucinogenic effects, is still the thing standing between any of this and a patient.
HHS is funding the first-ever government-backed ibogaine trials, through the Advanced Research Projects Agency for Health (ARPA-H) and the National Institute on Drug Abuse, targeting opioid use disorder and PTSD. It's a direct result of President Trump's April executive order, which committed $50 million to federal ibogaine research as part of a broader push to accelerate psychedelic drug development across agencies.
Before any of that money reaches a patient, the FDA opened a public comment docket (No. FDA-2026-N-10429, open through Nov 20) laying out just how seriously it's treating ibogaine's known cardiac risk. The proposed trial design requires continuous heart-rhythm monitoring for up to 36 hours after a single dose, in an inpatient unit equipped for life-threatening arrhythmia — a physician-led advanced-cardiac-life-support team, bedside defibrillator, emergency pacing, and ventilator support all on standby. Monitoring continues until the QT interval returns near baseline; if it stays above 500 milliseconds for more than two days, the study has to pause. Anyone with structural heart disease, a baseline QT above 430ms, or a personal or family history of arrhythmia or sudden cardiac death is excluded outright, and starting doses are capped at 10 mg/kg.
None of this is hypothetical caution. We've already covered the cardiac signal that stalled DemeRx's own ibogaine HCl program after a Phase 1 participant showed QTc prolongation — this FDA proposal reads like the regulatory response to exactly that kind of result, applied before the next trial even starts rather than after.
A new longitudinal study found that U.S. adults whose most intense psychedelic experience in a given two-month window fell on a date close to the 2024 Democratic or Republican National Conventions, or near Election Day, reported more support for partisan political violence afterward — while those whose peak experience landed on the Fourth of July reported less. Led by Otto Simonsson at Sweden's Karolinska Institutet and published Oct 6 in the journal Psychedelic Medicine, the study tracked nearly 22,000 U.S. adults across two 2023–24 survey waves; of the roughly 12,000 who completed both, 505 reported psychedelic use in the interval and gave the exact date and estimated dose of their most intense experience. About four in five of those users identified as Democrats. The study doesn't say whether this was recreational or more controlled use — participants reported only the date and dose, not the context, so "naturalistic" here just means "outside a clinical trial," nothing more specific.
We've all read that Grindr usage spikes in host cities during party conventions — add psychedelics to the list of things apparently also happening on the convention floor this cycle.
The researchers frame the actual finding through set and setting — the idea that a psychedelic experience is shaped by a person's mindset going in and the environment around them — extended to the broader cultural and political mood on a given day, not just the room someone is sitting in. One notable, unplanned finding: among the small number of Republican respondents whose session fell on the date of the July 2024 assassination attempt on Donald Trump, support for partisan violence went down, not up.
Read the caveats as seriously as the headline. This is observational, not a controlled trial, so it can't establish that the drug caused the shift rather than correlating with who was already paying close attention to politics that day. Only the Fourth of July comparison was pre-registered; the convention, election, and assassination-date findings are exploratory, drawn from subsamples as small as 19 people, without correction for running multiple comparisons. None of this means psychedelics cause political violence; it's a preliminary signal that when someone uses may matter, not just whether they do.
A Cornell student's lawsuit alleging she was gang-raped by Chi Phi fraternity members in October 2024, after being given alcohol and ketamine that left her unable to resist or leave, has reopened a criminal investigation that initially produced no charges. On Oct 1, New York Gov. Kathy Hochul named state Attorney General Letitia James as special prosecutor, after losing confidence in the local DA's handling of the case; a separate dispute has emerged over whether phone-record preservation letters Cornell police drafted in Nov 2024 ever reached prosecutors. The allegations are disputed — some of the named students say the sex was consensual, others deny contact entirely — and nothing here is adjudicated. We're not re-reporting the legal case; PBS NewsHour and CNN are covering it in depth.
What's squarely in our lane is the pharmacology, because it's the same compound we've covered as a patent story and have an encyclopedia entry on: ketamine is an NMDA-receptor antagonist that produces dissociation, amnesia, and immobility at doses around 1.0–1.5 mg/kg IV or 3–4 mg/kg IM — the same mechanism underlying Spravato, an FDA-approved rapid-acting antidepressant for treatment-resistant depression, and the one that makes a person unable to resist or clearly recall what happened to them when it's administered without their knowledge. In a clinic, that dissociative state happens under supervision, with dosing controlled and consent established beforehand — the entire premise of ketamine-assisted therapy is that the setting and the consent are what make the drug's effects therapeutic rather than dangerous. Outside that setting, the same pharmacology is what makes ketamine one of the drugs documented in drug-facilitated sexual assault cases: a person can be conscious, compliant-looking, and have no reliable memory of it afterward.
The harm-reduction basics bear repeating because they're not abstract: never leave a drink unattended, watch drinks being poured, and know that a dissociative, amnesia-producing dose doesn't require a struggle to be incapacitating — the absence of resistance is not the same thing as consent. This is harm-reduction and pharmacology reporting, not legal commentary on an active, disputed case, and not medical advice.
One week after the FDA's historic public hearing on psychedelics — the one that drew over 1,800 registrants — the DEA published a proposed rule doing close to the opposite: placing five tryptamines in Schedule I. The compounds are 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT, published in the Federal Register Sept 23, 2026, with public comments due Oct 23.
The DEA's own cited evidence is thin: 518 law enforcement encounters and 65 poison-center exposure cases across an 18-year span (2003–2021), with zero deaths reported from single-substance exposures. The agency's filing even acknowledges the FDA found "no diversion from research or legitimate manufacturing." This is the DEA's second attempt at scheduling these specific compounds — it withdrew a similar effort in 2022 after public and legal pushback.
The real collision: one of the five, 4-OH-DiPT, is the parent compound behind Reunion Neuroscience's luvesilocin (RE104) — a patented prodrug that the FDA granted Breakthrough Therapy Designation for postpartum depression back in February 2026, on the strength of a Phase 2 trial where 70% of patients on the 30mg dose were in remission at both Day 7 and Day 28. Reunion is now working with the FDA on a single pivotal Phase 3 trial — funded privately after MPM BioImpact took the company off Nasdaq in a 2023 buyout, so there's no public ticker to watch this through. A Schedule I listing for the parent compound wouldn't necessarily halt luvesilocin's own development path, but it sets up a direct tension between two federal agencies moving in opposite directions on the same chemical scaffold.
"Schedule I has become the default for the DEA for any substance that is not FDA-approved," said Robert Rush of the Rights and Reason Project, calling out the contradiction directly: "We have the FDA attempting to move forward a promising new treatment while the DEA is doing everything they can to obstruct." MAPS's Ismail Ali put it more simply: "These five lesser-known psychedelic substances don't belong in Schedule I."
Dr. Sunil Aggarwal's petition to move psilocybin from Schedule I to Schedule II under the Controlled Substances Act — first filed in February 2022 — has been sitting at the Department of Health and Human Services since the DEA forwarded it there for scientific review on Aug 11, 2025. Fourteen months later, per Marijuana Moment, HHS still hasn't responded, and no timeline has been disclosed. Attorney Kathryn Tucker, representing Aggarwal, argues the DEA should "promptly move forward" in light of Trump's psychedelics executive order — but as of this writing, the order hasn't translated into movement on the one rescheduling petition actually working its way through the federal process.
This sits alongside the state-level picture we scored bill-by-bill a few days ago: most of the real legislative action in 2026 has happened in state capitols, not at the federal scheduling level, and a stalled HHS review is a real part of why.
AtaiBeckley (Nasdaq: ATAI) — the company Eli Lilly is paying up to $3.8 billion to acquire for BPL-003, its synthetic 5-MeO-DMT drug — has open-label extension data worth flagging that predates this site's coverage. Announced Nov 10, 2025: patients who got an initial active dose (8 mg or 12 mg) in the core Phase 2b study, then a second 12 mg dose eight weeks later, hit 63% response and 48% remission by Week 8 of the extension, for treatment-resistant depression. Two doses eight weeks apart produced antidepressant effects lasting up to four months. That data helped lock in the 8 mg dose for the pivotal Phase 3 program, branded ReConnection, now underway — though topline results aren't expected until around 2029.
Worth being precise about which company is which here, since it's an easy mix-up (one we briefly made ourselves pulling this together): 5-MeO-DMT is being developed in parallel by two separate companies with two separate drugs — AtaiBeckley's intranasal BPL-003 and GH Research's inhaled GH001 — and the datasets aren't interchangeable. Full trial history, including both programs side by side, is in our trials tracker.
This is business and clinical-trial reporting, not medical advice. BPL-003 remains investigational and is not FDA-approved for any use.
Our own anxiety-drug market piece scoped Definium Therapeutics' (Nasdaq: DFTX) DT120 — an orally-disintegrating LSD tablet — to its two positive Phase 3 trials in generalized anxiety disorder. That undersold it. DT120 also has a positive Phase 3 win in major depressive disorder: Emerge, which read out June 22, 2026, showed a -8.1 point placebo-adjusted improvement on the MADRS depression scale at Week 6 across 149 participants (p<0.0001) — rapid (-14.2 points at Week 1) and durable (-7.3 points at Week 12). The FDA granted DT120 Breakthrough Therapy Designation for depression on Aug 27, 2026 on the strength of that result. A second, confirmatory MDD Phase 3 (Ascend, roughly 175 participants) dosed its first patient May 12, 2026, with topline data expected in 2027.
Between the anxiety and depression programs, that's three of Definium's four late-stage readouts positive so far — arguably a bigger story than the anxiety angle alone, and one worth correcting for here. Full trial history is in our trials tracker.
This is business and clinical-trial reporting, not medical advice. DT120 remains investigational and is not FDA-approved for any use.
Clearmind Medicine (Nasdaq: CMND) hadn't shown up in our patent tracker or trials tracker before now — a gap in our coverage, not a new company. Two real developments this month: on Sept 11, the company enrolled its first actual alcohol-use-disorder patients (at Hadassah Medical Center in Jerusalem) in a trial of CMND-100, its oral formulation of MEAI — a non-hallucinogenic, psychedelic-derived compound distinct from any classic psychedelic, working through serotonergic and alpha-2-adrenergic receptors rather than the 5-HT2A pathway behind classic psychedelic effects. Then on Sept 23, the company disclosed three new US patent applications covering combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (like PEA) — developed with NeuroThera Labs, aimed at depression, PTSD, pain, and substance-use disorders.
Company-reported figures put its broader portfolio at 19 patent families and 32 granted patents as of June 2026. We independently verified one — a MEAI-covering patent (US 12,357,590, "Binge Behavior Regulators") expiring Dec 3, 2037 — and have added the company to both trackers with that verification status noted plainly rather than taking the full portfolio figure on faith.
This is business and clinical-trial reporting, not medical advice. CMND-100 remains investigational and is not FDA-approved for any use.
A study published Sept. 3 in Science found that giving mice a dose of psilocybin before chemotherapy prevented much of the nerve damage and lasting pain that platinum-based drugs like cisplatin commonly cause — without blunting the chemo's effect on the tumors themselves. Mice given chemo alone stayed hypersensitive to pain for at least four months afterward; one dose of psilocybin beforehand cut that to about three months, and two doses given a week apart eliminated the hypersensitivity entirely, according to the MD Anderson Cancer Center team behind the work.
"The idea, instead of trying to put things back together that are broken, is to jump in and protect it from the very beginning," says study co-author Patrick Dougherty, a pain researcher at MD Anderson. Follow-up lab work suggests the mechanism may hold in human nerve cells too — psilocybin blocked cisplatin's disruption of mitochondrial transport inside neurons grown in a dish.
This is mouse and cell-culture data, not a human result yet, and it's worth being precise about that distinction. Cornell neuroscientist Alex Kwan, who wasn't involved in the study, called the effect "quite incredible" but said he'd want more data before drawing conclusions about people; University of Sydney neuroscientist Susanna Park raised a similar caution, noting a "large gap" in this field generally "between success in preclinical models and translation to effective therapies for humans." MD Anderson plans to launch a phase 2 trial next month testing psilocybin in roughly 80 patients undergoing chemotherapy for breast, colorectal, or head and neck cancer — the same phase-by-phase process we've broken down in detail before, and one that typically takes years to produce a definitive answer.
One detail for patients who'd rather not trip during cancer treatment: the same team tested an experimental, non-hallucinogenic psilocybin-like compound and found it replicated some of the protective effects in mice.
This is science reporting, not medical advice. Psilocybin remains a Schedule I substance in the US and is not an approved treatment for chemotherapy-induced nerve pain — this specific protective effect has so far only been demonstrated in mice and isolated cells, not people.
Ari Emanuel — the WME/Endeavor chief whose temper was the real-life template for Entourage's Ari Gold, and who now owns UFC, WWE, and a chunk of London's West End — has a new memoir out, Roll the Calls. In a wide-ranging interview with The Sunday Times Magazine, Emanuel — whose rage is well documented, by his own admission and everyone else's — credits a session with 5-MeO-DMT, the compound our own encyclopedia entry calls the "God Molecule," with taking real edge off it.
"I recently met a shaman in Santa Fe, New Mexico, and took 5-MeO-DMT, produced by the Sonoran Desert toad," Emanuel tells the paper. "I've explored many [hallucinogenics], but I think that's the most powerful. You realise you're a pimple on the ass of an ant. It's been an incredible help to me to disavow a bunch of shit. And give myself and my life and my parents a break." He's candid that it hasn't switched the anger off entirely — "Recently, somebody did something and I hit the rage button. Defcon one," he says, though he adds that this time he "put the call on mute" instead of yelling.
It's a striking, very public data point for a compound we've covered from the inside before — see our own personal account of a Bufo session — but it's one man's story, not a treatment. 5-MeO-DMT remains a Schedule I substance in the US with no approved medical use, "shaman"-led sessions are unregulated and carry real physical and psychological risk, and nothing here is a substitute for actual anger-management or mental-health care.
Host James W. Jesso's latest episode skips the neuroscience and the legal status — both of which we cover elsewhere, including our own ibogaine patent deep-dive and the first FDA-cleared ibogaine-derivative trial — and spends an hour on what a full "flood dose" of ibogaine subjectively feels like, with guest Jonathan Dickinson, CEO of Ambio Life Sciences, one of the larger ibogaine retreat operators, and author of the 2026 book Ibogaine and the Bicameral Mind. The two go through sensory overload, auditory hallucination, and the "life review" phenomenon users commonly describe — some report encounters with deceased loved ones or prophetic-feeling visions, which Jesso and Dickinson discuss as subjective phenomenology, not evidence of anything beyond the brain.
To their credit, the episode doesn't skip the real risks either — ibogaine's documented cardiac danger and the cost and liability of leaving the US for unregulated treatment both get airtime. Still, this is a first-person account from a retreat operator with a direct financial stake in ibogaine tourism, not independent journalism — read it as testimony, not reporting.
New chemical analysis is confirming something archaeologists have suspected for decades: Chavín de Huántar, a 3,000-year-old pilgrimage complex high in the Peruvian Andes, ran on drug rituals. In 2016, a team led by Stanford's John Rick began excavating a newly found underground gallery that yielded what he calls "the smoking gun" — 21 bone snuff tubes. "It was crazy, we started to find all this material," says Oscar Espinoza, the Tulane Ph.D. student who ran the analysis, published in May 2025. The tubes carried residue of tobacco and seeds from the vilca tree — a mix of bufotenine, DMT, and 5-MeO-DMT that produces short, extremely intense visions.
The pattern spreads well beyond Chavín, according to a new Science feature by Andrew Lawler. At San Pedro de Atacama in Chile, home to a 400,000-object collection assembled by a local priest, ethnobotanist Constantino Torres says drug paraphernalia from the Tiahuanaco era (roughly 250-1000 C.E.) turns up in "roughly one in three graves" — among them bird-bone tubes that archaeologist Verónica Lema identified as enema syringes with "millimeter-precise dosing openings." The Wari empire, meanwhile, appears to have spiked feasting chicha beer with ground vilca seed for a subtler, longer-lasting group effect. "I might have a vilca beer with you, [even if] I'm not going to snort that stuff," says archaeologist Justin Jennings — a bonding "afterglow" he compares to what modern ayahuasca users report. A separate 2018 discovery in Bolivia, a leather bundle of snuff tools analyzed by chemist Melanie Miller, produced the first direct evidence that ayahuasca's own ingredients were being traded into the Andean highlands at all, as early as 250-550 C.E.
Not everyone is convinced how far to take this: Lema, who also worked on the Chavín lab analysis, cautions there isn't yet enough evidence to say what was actually happening in those galleries, or for whom. But the pilgrimage never really stopped — Chavín now has two psychedelic retreat centers operating in its literal shadow. "These plants are powerful tools of knowledge, allowing access to different dimensions," says Ingrid Diaz, who runs one of them. Archaeologist Matt Sayre, who still excavates at the site, says modern visitors have occasionally bribed the park's guards to sneak in after dark.
Three days after the FDA's psychedelic-drugs hearing drew over 1,800 registrants, MAPS put its reaction on the record. Co-executive director Betty Aldworth: "The importance of therapy to these treatments cannot be understated — and it wasn't." Co-executive director Ismail Ali, J.D., was more direct: "Breakthrough clinical findings are promising, but mean little if the systems around them are not prepared to deliver them to patients." MAPS says it will submit formal written testimony to the FDA's public docket (open through Oct 5) addressing three specific gaps: systems readiness, therapist training capacity, and patient access — echoing the same provider-training and access themes the hearing itself surfaced. Separately, MAPS shared its recently published, open-science Ibogaine Investigator's Brochure directly with HHS, FDA, and the VA — a concrete document handoff, not just commentary. None of this changes the regulatory timeline on its own, but it's a marker of who's showing up to shape it: MAPS has pushed psychedelic policy since 1986 and has deployed over $150 million in philanthropic funding toward exactly this kind of infrastructure question.
One term worth slowing down on today, straight off yesterday's news.
DT120: Definium Therapeutics' lead LSD candidate — lysergide delivered as an orally-disintegrating tablet, rather than the traditional blotter or liquid form. It was developed under the code name MM120 before the company's January 2026 rebrand from MindMed to Definium. DT120 has now posted two independent positive Phase 3 trials for generalized anxiety disorder — Voyage and Panorama — making it the most advanced LSD program in clinical development, though it's still not FDA-approved for anything.
Full entry, plus 157 other terms, is in our Encyclopedia.
Panorama, Definium's second Phase 3 trial of DT120 (lysergide) for generalized anxiety disorder, met its primary endpoint on Sept 14 — a statistically significant and clinically meaningful improvement over placebo on the Hamilton Anxiety Rating Scale, across 245 participants. That's two-for-two: Panorama follows Voyage, DT120's first Phase 3 GAD trial, which also hit its primary endpoint back in August — full history on our Trials Tracker. Two independent positive Phase 3 readouts for the same drug and indication is a meaningfully stronger position than one — it's the kind of replication regulators specifically look for, and part of why Definium is currently the most valuable public psychedelic-adjacent company by market cap. DT120 still isn't FDA-approved for anything; an NDA filing hasn't been announced yet.
Yesterday's FDA public hearing — the one set up by this week's NEJM framework piece — drew over 1,800 registrants, hybrid in-person and virtual. FDA's Marta Sokolowska opened by framing it as "a whole of government effort to better understand the opportunities, challenges, and public health considerations" around psychedelic drug treatment. Panelists heard roughly 80 comments across two thematic waves: one on provider training, credentialing, and patient safety; the other on access and standardizing how outcome data gets collected across different providers and settings. None of this is a decision — it's the FDA listening, not ruling — but it's a real, sizable signal of how much public and clinical interest has built around psilocybin and methylone specifically, the two compounds furthest along the agency's own priority-review track. Worth noting: Michael Davis, FDA's newly appointed CDER director and lead author on this week's NEJM framework piece, spent years as Chief Medical Officer at Usona Institute — the nonprofit running one of the field's furthest-along psilocybin trials — before joining the agency now hearing the case for approving it.
DMT (N,N-Dimethyltryptamine): a classic psychedelic found naturally in plants and animals, and the principal psychoactive ingredient in ayahuasca. A single dose reversed depression-like symptoms in stressed mice by regrowing brain cells, according to research we've covered — animal data, not a human result yet.
Bicycle Day: April 19, 1943, the date Albert Hofmann deliberately dosed himself with 0.25mg of the LSD he'd synthesized five years earlier, then rode his bicycle home through Basel as the effects took hold — now marked informally every year as a psychedelic holiday. Hofmann himself later described becoming convinced his neighbor was a malevolent witch and that the drug had poisoned him — a real account of how disorienting an unplanned first dose can be, even for the person who invented the compound.
Full entries, plus 156 other terms, are in our Encyclopedia.
Four senior FDA officials — Michael Davis, Teresa Buracchio, Tiffany Farchione, and Bernard Fischer — published a perspective piece in the New England Journal of Medicine on Sept 9-10 laying out how the agency plans to actually evaluate psychedelic drugs, days ahead of today's public hearing on the topic. The piece confronts the field's core methodology problem directly: functional unblinding rates in psilocybin trials routinely exceed 80%, since it's hard to hide from a patient (or their clinician) that they just took a psychedelic. Rather than pretending the standard placebo-controlled model works here, the framework proposes active-placebo conditions, measuring patient expectancy at baseline, and statistical models that treat the therapeutic alliance itself as a variable to control for — not just accept as noise. It follows the FDA's finalized clinical-trial guidance from July and sets up the terms for today's hearing, where the agency is expected to hear public input on exactly these design questions.
We spent the past week tracking down every dollar we could verify moving through the psychedelic-therapeutics sector — public company market caps, private funding rounds, and government research budgets — and ranked what's left after correcting nine claims that didn't hold up. The gap between the three is the real story: over $11 billion in public market cap, $1.6 billion in disclosed private funding, and barely $140 million in verified government funding worldwide. Read the full rankings here. Part two, the trends and the graveyard, follows next Friday.
Governor Jenniffer González-Colón signed Executive Order 2026-037 on August 4, directing Puerto Rico's Department of Health to evaluate a pilot clinical research program covering ibogaine, psilocybin, and MDMA, with veterans first in line if it moves forward. The order creates a Scientific and Regulatory Advisory Committee — psychiatrists, pharmacologists, ethicists — to weigh the evidence, assess what infrastructure the island would need, and pursue funding and partnerships with the NIH, FDA, VA, and DEA. It's explicitly a feasibility study, not a green light: the order states outright that it does not authorize any clinical use of these compounds yet. That puts Puerto Rico alongside a growing list of U.S. jurisdictions — Texas, Colorado, Connecticut, New Jersey — exploring psychedelic research pilots ahead of any federal approval, each with its own scope and guardrails.
One term worth slowing down on today — picked from what readers are actually searching for.
Anandamide: the body's own natural cannabinoid, discovered in 1992 and named from the Sanskrit "ananda" (bliss). It binds the same receptors as THC and is sometimes called the "bliss molecule" — unrelated to classic psychedelics, but part of the same broader neurochemistry-of-wellbeing territory.
Example: A 2003 study (Sparling et al., published in NeuroReport) found anandamide levels rise in the blood after 50 minutes of moderate-intensity running or biking — real evidence for what's now considered the leading explanation of "runner's high." Unlike endorphins, anandamide is small and fat-soluble enough to cross the blood-brain barrier, which is part of why researchers now think it's a bigger piece of that effect than endorphins ever were.
Full entry, plus 155 other terms, is in our Encyclopedia.
A Wall Street Journal investigation traces a network of SpaceX and Tesla insiders funding psychedelic research and drug development. Antonio Gracias — a SpaceX director and Valor Equity Partners founder — personally cut a $25 million check from his family foundation to recapitalize what's now Resilient Pharmaceuticals after its 2024 FDA rejection, then moved the company to Chicago and took it over — an idea reportedly pitched to him by MAPS founder Rick Doblin at a Burning Man gathering in 2024. Gracias also endowed a $16 million psychedelics-in-society professorship at Harvard back in 2023. Fellow SpaceX director Steve Jurvetson and his wife Genevieve — a board member of the Psychedelic Science Funders Collaborative — have long supported MDMA trial funding, and Kimbal Musk and his wife Christiana have backed a separate academic fellowship. Elon Musk himself has disclosed a ketamine prescription for depression and has spoken favorably about MDMA. The piece also connects the dots to the DoD's active-duty MDMA-PTSD trials and April's presidential executive order fast-tracking psychedelic drug review — which Trump has said Joe Rogan prompted him toward, specifically on ibogaine.
Eli Lilly announced on July 16, 2026 that it will acquire AtaiBeckley — the company formed just months earlier when ATAI Life Sciences merged with Beckley Psytech — for $6.75 per share in cash upfront (about $2.8 billion) plus up to $2.50 per share more through a contingent value right tied to future milestones, putting the deal's total potential value at $3.8 billion. The acquisition is expected to close this quarter and is the first time a major pharmaceutical company has bought a psychedelic drug developer outright, rather than licensing or partnering. The deal centers on AtaiBeckley's 5-MeO-DMT candidate mebufotenin (BPL-003), which posted positive Phase 2b results for treatment-resistant depression earlier this year. It's a genuinely new kind of signal for the sector: after years of biotechs partnering with or licensing individual compounds to Big Pharma, this is the first full buyout — the closest thing yet to an answer on whether Big Pharma sees this as a real, ownable business or just a research bet worth watching from a distance.
New Zealand's medicines regulator, Medsafe, has approved two named psychiatrists — Dr. Gary Wynn in Wellington and Dr. Tom Paterson in Auckland — to prescribe pharmaceutical-grade MDMA as part of supervised psychotherapy for adults with PTSD that hasn't responded to conventional treatment. Each spent more than a year in the approval process. It's a narrow authorization, not a general legalization — access runs through exactly two clinicians for now — but it puts New Zealand in the same authorized-prescriber lane Australia opened for MDMA-assisted therapy back in 2023, while the U.S. still has no approved MDMA therapy on the market: Resilient Pharmaceuticals' resubmitted application (branded Rysanso) remains under FDA review with no decision yet.
Two more terms worth slowing down on — one pharmacology, one slang worth knowing precisely rather than guessing at.
Eugeroic: a class of wakefulness-promoting drugs, distinct from classic stimulants, that increase alertness without the same peripheral sympathetic activation. Modafinil is the prototypical example. Not a psychedelic at all — it shows up adjacent to this space mainly because people sometimes reach for eugeroics and psychedelics for overlapping reasons like focus or cognitive enhancement, despite the two drug classes working through entirely different mechanisms.
Space Jam: drug slang, not a Warner Bros. reference. In DEA slang documentation, "space" refers to PCP combined with cocaine, and "space jammin'" describes the disorienting, out-of-body-feeling high from combining the two. Polydrug combinations like this carry real, elevated risk precisely because the effects and interactions of the mixture are far less predictable than any one substance alone.
Full entries, plus 153 other terms, are in our Encyclopedia.
2C-B: a synthetic phenethylamine psychedelic with combined empathogenic and visual effects. Alexander Shulgin first synthesized it in 1974, called it part of his "magical half-dozen" of noteworthy phenethylamines, and described the effect as a "warm hug." A real safety note, not folklore: 2C-B is metabolized in part by the same MAO enzymes an MAOI blocks, and case reports link the combination to agitation.
MAOI (Monoamine Oxidase Inhibitor): an enzyme inhibitor that prevents the breakdown of DMT in the gut, which is what makes ayahuasca psychoactive when taken orally. Outside psychedelics entirely, MAOIs carry a genuine dietary restriction — combined with tyramine-rich foods like aged cheese or cured meats, they can trigger a real hypertensive crisis, not just an unpleasant interaction.
Full entries, plus 146 other terms, are in our Encyclopedia.
A trademark filing reveals what Resilient Pharmaceuticals (formerly Lykos, before that MAPS PBC) is calling its resubmitted MDMA-PTSD candidate: Rysanso, filed to cover pharmaceutical and psychedelic preparations. We've covered the resubmission itself — this doesn't change where that stands, but a brand name this far ahead of any approval is its own signal: the company is positioning for a market launch, not just another regulatory round. Read into the name what you want — it lands somewhere between "resilience" and "renaissance," which tracks for a drug that's already survived one rejection and a company-wide rename.
Under the new CBA finalized in May 2026, the WNBA removed cannabis from its prohibited substances list entirely, while adding psilocybin, psilocin, DMT, and ibogaine to it for the first time — the two drug categories moving in opposite directions in the same document. It's a small, specific data point in a much bigger pattern: legal and cultural comfort with cannabis keeps growing while psychedelics remain treated as the newer, less-settled risk, even as federal research funding and executive-branch attention move the other way. Worth noting the practical side too — several of the newly-banned compounds clear the bloodstream within 24 hours, which limits how much a ban like this can actually detect after the fact.
Mescaline: the psychedelic alkaloid found in peyote and San Pedro cacti, with ceremonial use tracing back well before any clinical interest existed. The Native American Church, founded in 1918 out of a peyote ceremony practiced since the 1880s among the Kiowa and Comanche, holds the only federal legal exemption of its kind in the US — see our Peyote Exemption entry for how that carve-out actually works.
DEA (Drug Enforcement Administration): the federal agency that would have to reschedule psilocybin, MDMA, or LSD out of Schedule I before an approved drug based on them could actually be prescribed. It hasn't done that, but in a January 2026 final order it raised the legal research-production quota for psilocybin from 30,000 to 50,000 grams and for 5-MeO-DMT from 11,000 to 30,000 grams — more supply for research, short of rescheduling anything.
Full entries, plus 140 other terms, are in our Encyclopedia.
We just came across this one — published August 3 in Nature Communications, so not breaking, but worth surfacing. Researchers at the University of Southern Denmark, led by Mikael Palner and Frederik Gudmundsen, used PET scans to track brain activity in rats given LSD, psilocybin, and 2C-B, both during the acute trip and a week later. The three drugs didn't converge on one shared pattern the way "classic psychedelic" as a category might imply: 2C-B mainly hit reward-related regions, LSD hit areas tied to habit and motivation, and psilocybin stood out for hitting emotion-processing regions specifically. If this replicates in humans, it's a real argument against treating psychedelics as interchangeable for a given condition — the right compound may depend on which circuit actually needs to change.
We missed this one when outgoing Governor Phil Murphy signed it on January 20, 2026, days before leaving office. S2283 creates the Psilocybin Behavioral Health Access and Therapy Pilot Program — a narrow, hospital-based research program supervised by the state Department of Health, with $6 million appropriated to run it. Worth being precise about what this actually is: despite headlines at the time suggesting New Jersey had "legalized" psilocybin, it hasn't. This creates no public access — it's a state-sanctioned clinical research pathway, similar in shape to Connecticut's expanded pilot and Louisiana's opioid-settlement-funded program, joining a growing list of states building this kind of infrastructure ahead of any federal approval rather than waiting for one.
We just came across this one and thought it was worth surfacing, even though it's not fresh — the underlying paper published in JACS in late 2025, and UC Davis put out its own writeup on January 7, 2026. Chemists Joseph Beckett and Trey Brasher, working with professor Mark Mascal, used a photochemistry technique — fusing tryptamine to amino acids with ultraviolet light — to generate candidate molecules from a library of 100 computationally modeled compounds. One of them, labeled D5, fully activated the 5-HT2A receptor without producing the head-twitch response mice show in response to actual hallucinogens. Brasher called it "the discovery of a brand-new therapeutic scaffold" — a genuinely new chemical starting point, not a tweak on an existing psychedelic, if it holds up in further testing well beyond a mouse-model screen.
Set and Setting: mindset and environment shaping the experience — a phrase that sounds like vibes but has real safety weight behind it. Our reporting on overseas clinic safety found that poor setting — unscreened staff, no medical oversight, patients dosed without real preparation — was a common thread across the worst documented outcomes, not just an aesthetic afterthought.
Fear Extinction: the process by which a learned fear response fades when the feared stimulus keeps occurring without the bad outcome attached to it — a leading model for how trauma therapy works. Animal studies found MDMA enhances this process through a BDNF-dependent mechanism in the amygdala, a proposed reason the VA's MDMA-PTSD trials pair the drug with therapy sessions rather than administering it alone.
Full entries, plus 140 other terms, are in our Encyclopedia.
We missed this one when Governor Ned Lamont signed it on June 4 — bubbling it up now because it's a bigger structural change than the headline size suggests. SB 191 passed the Connecticut Senate 35-0 and House 122-27, expanding a small, Yale-run pilot that had covered about 20 veterans into a program open to any adult 18+ who meets clinical criteria, including first responders and frontline health care workers with treatment-resistant depression or PTSD. The program stays under a state medical school's FDA-approved research umbrella — this isn't open access, it's still a supervised research pathway. The detail worth noting: the new law also removes the original sunset clause that would have ended the pilot once federal approval happened, which reads less like a stopgap now and more like Connecticut building permanent infrastructure ahead of an approval it expects to actually arrive.
Brazil's Federal Public Prosecutor's Office (MPF) in Acre issued two formal recommendations on September 2, 2026, pushing the National Council on Drug Policy (CONAD) and the health regulator Anvisa to convene working groups and update the country's ayahuasca and DMT rules — the first real push to revisit a framework that's stood since 2006. That original rule drew a sharp line: religious ceremonial use was protected, but commerce, tourism, advertising, proselytizing, and therapeutic use explicitly were not. Two decades on, all of those lines have blurred — ayahuasca churches have grown internationally, secular retreat tourism has expanded, and therapeutic framing has become far more common, which is the pressure the MPF's recommendations are responding to.
The author, Henrique Fernandes Antunes, is Chacruna's Research Director and wrote the 2025 book Religion, Drug, or Cult? Ayahuasca's Legal Path in Brazil, the United States, and France — he's one of the more credentialed people writing on this specific question. Worth reading alongside our own country-by-country look at DMT's legal status in Europe: Brazil is ayahuasca's country of origin and still hasn't settled this, which says something about how unresolved the legal question remains even where the practice is oldest and most established. As of this writing, CONAD and Anvisa haven't publicly responded to the recommendations.
Two more terms that come up constantly and rarely get explained plainly.
5-HT2A Receptor: the single receptor that psilocybin, LSD, DMT, and mescaline all act on as agonists, despite looking chemically quite different from each other. It's also why an antagonist at the same receptor can block a trip outright — see our Antagonist entry in the Encyclopedia. Definium's LSD-derived DT120 works through this exact receptor; we've covered where that drug and its patents stand.
Microdosing: taking a sub-perceptual dose, too small to produce a noticeable trip. The open-label, self-report evidence is enthusiastic. The rigorous evidence isn't there yet — a 2026 microdosed-LSD depression trial we covered looked strong with no control group, then failed to beat an active placebo once one was added. A useful reminder that open-label results and controlled results can point in opposite directions for the same compound.
Full entries, plus 140 other terms, are in our Encyclopedia.
Psychedelic coverage throws around a lot of jargon fast, so twice a week we're slowing down on two terms at a time.
Default Mode Network (DMN): the brain network active during self-referential thinking — mind-wandering, autobiographical memory, the running mental narrative about yourself. Neuroscientist Robin Carhart-Harris's "entropic brain" hypothesis proposes psychedelics work partly by collapsing this network's normal organization. When his team first scanned brains on psilocybin, they expected to see more activity and instead found a significant drop-off — the opposite of the prediction they went in with, and part of why the DMN became central to modern psychedelic neuroscience.
Ego Dissolution: the temporary loss of the felt boundary between self and everything else, one of the most commonly reported effects at higher psychedelic doses. Researchers measure it with the Ego-Dissolution Inventory, an 8-item scale validated in 2016. Scores on it rise with psychedelic dose but not with cocaine or alcohol dose — part of why researchers treat it as a specific, measurable effect rather than generic intoxication.
Full entries, plus 97 other terms, are in our Encyclopedia.
Ibogaine's original patents belong to Howard Lotsof, who discovered its anti-addictive effect on himself in 1962 and patented it in 1985 — all long expired. We mapped who holds the 53 patents filed since, and found that DemeRx's original opioid-use-disorder program stalled over a cardiac safety signal and ended in litigation with atai, while a different DemeRx drug, for a different disease, became the first ibogaine-class compound cleared for a US trial. Read it here.
Michigan's HB 6020, a bipartisan bill from Reps. Jaime Greene and Matt McFall, would put $50 million of the state's opioid settlement money into FDA-supervised ibogaine trials for opioid use disorder, PTSD, and other conditions — the same settlement-funding playbook Louisiana adopted a few weeks ago. What makes it more than another state pilot: Michigan would join a consortium — states, drug manufacturers, health systems, and research universities — that's reportedly grown to six states in under a year, aiming to pool each state's trial data into a single, consolidated New Drug Application to the FDA. If that actually holds together, it's a genuinely novel end-run around the fact that no single state can get a drug approved on its own — states can generate the data, but the FDA still has to accept a joint submission built that way, which has no real precedent we're aware of. Worth tracking, not yet a sure thing.
Researchers mapped nearly half a million individual brain cells from hippocampal tissue, comparing people with major depressive disorder to controls at single-cell resolution — the largest dataset of its kind. Adult neurogenesis, the hippocampus's ongoing production of new neurons throughout life, was measurably stalled in the depression group, alongside broader molecular disruptions in synaptic function, energy metabolism, inflammation, and cellular stress response. It's descriptive, not interventional — the study shows what's different in depressed brains, not that fixing neurogenesis treats depression — but it's a plausible mechanistic thread connecting to why several psychedelics and ketamine, which promote neuroplasticity and in some cases new neuron growth in animal models, show antidepressant effects distinct from traditional SSRIs.
Ketamine tops our patent tracker at 71 granted patents — more than psilocybin, more than MDMA — and almost all of it traces to one drug, Spravato. We dug into why the compound already approved and already prescribed isn't getting the gold-rush treatment the still-illegal psychedelics are. Read it here.
The drugs most Americans take for depression and anxiety are decades-old generics that make pharma almost nothing. We mapped the five newer, still-patented drugs actually driving revenue in this space — and how fast two of them are about to lose that protection. Read the brief here.
Border Force seized 1,300kg of ketamine in Q1 2026 alone — on pace to blow past the previous full-year record. That prior record, set in the year to March 2025, was itself 1.3 tonnes, a 55% jump from the year before, per Home Office data. If the pace holds, 2026 could roughly double the seizure total in a single year. We're covering the demand side of this the same week: why ketamine's patent-free, already-generic status has kept it out of the psychedelic industry's speculative gold rush even as use — and now interceptions — climb.
SB 43 became law on August 1 without Governor Jeff Landry's signature, after passing both chambers unanimously in May. It creates a psychedelic-assisted therapy pilot inside the Louisiana Department of Health, funded by the roughly $600 million the state is due through 2038 from opioid settlement payouts — money extracted from the companies that helped cause the crisis, redirected toward trials of psilocybin, ibogaine, and MDMA for opioid use disorder and co-occurring conditions. Any studies still have to clear the FDA's investigational drug process and get DEA Schedule I permits like anyone else's would. If a drug developed through the program is ever approved, the state gets a 20% cut of the profits — a funding model we haven't seen elsewhere in this space.
Normal antibodies are too large to get inside a cell, which rules them out against disease-causing proteins that never leave the cytoplasm — a real problem for neurodegenerative disease, where a lot of the damage happens intracellularly. A University of Essex team used AI to redesign 672 existing antibodies into "intrabodies," small enough to fold correctly and function inside human cells, targeting proteins implicated in Alzheimer's, Parkinson's, Huntington's, and motor neurone disease. Published in Nature Communications. It's a platform result, not a treatment — no human dosing data exists yet — but combined with gene-therapy delivery methods, it's a real answer to a targeting problem that's mostly kept intracellular disease proteins out of reach.
A New York Times investigation into overseas psychedelic clinics — most of it centered on Mexico, now home to at least 40 ibogaine clinics versus almost none a decade ago — puts real numbers behind something we've flagged before: there's no standardized oversight in this industry, and no official tally of how often that goes wrong. The anchor data point comes from a JAMA study led by Baylor's Amy McGuire, which surveyed 49 publicly-advertised psychedelic retreats and clinics in the US and abroad and found fewer than half employed a medical professional at all, and only about 10% had staff with emergency medical training. The Times ties that gap directly to documented harm: a fatal ibogaine-related cardiac arrest in Costa Rica (Aug 2024), a death during drug detox at a Mexican clinic (2025), a fatal ayahuasca reaction in Peru (Jun 2026), a Miami doctor now charged with manslaughter after a ketamine/MDMA death at an unlicensed "healing space," and a criminal rape case against a doctor at a Cancún ibogaine clinic, after he allegedly assaulted a patient who'd just been given 5-MeO-DMT. None of this is an argument that the underlying compounds don't work — the same reporting includes patients with real, positive outcomes — but it's a sharp illustration of what "no FDA approval, no standardized protocol, no US legal recourse" actually looks like in practice for the veterans and civilians we've written about traveling abroad for treatment that isn't yet legal at home.
The Army dosed 7,000 soldiers with psychedelics they weren't told they were taking, decades before Schedule I ended the program. We mapped where MDMA, psilocybin, ibogaine, ketamine, and LSD actually stand across the VA and Pentagon today — this time by consent. Read it here.
LSD has the smallest patent footprint of any compound in our tracker — 14 granted, 34 pending — and Roche's five grants turn out to be drug-testing patents, not therapeutics. Definium, the company closest to an actual approval, holds just one. Read the full breakdown here.
We missed this one when it happened back on July 22 — bubbling it up now because it's more consequential than the news cycle at the time gave it credit for. The House passed its version of the FY2027 defense authorization bill, 216-212, carrying two psychedelics amendments: one extends the Pentagon's psilocybin, MDMA, ibogaine, and 5-MeO-DMT research program for PTSD/TBI in active-duty service members from a 3-year window to 2033, the other codifies Trump's April 2025 psychedelics executive order into law and requires the VA to name an official within 90 days to coordinate psychedelic-therapy access across agencies. Ten co-sponsors, split roughly evenly R/D, led by Rep. Morgan Luttrell (R-TX). It still needs the Senate, which hadn't acted on it as of this writing — this is House passage, not final law.
5-MeO-DMT has 164 patents in play across our tracker, and Turtle Bear Holdings and Beckley Psytech hold the most — but the company with the strongest clinical data, GH Research, holds almost none of them. We dug into what that split says about how differently these companies are betting on the same compound. Read the full breakdown here.
Psilocybin leads every compound in our patent tracker on combined activity, and four holders — COMPASS Pathways, Enveric Biosciences, Turtle Bear Holdings, and CaaMTech — account for most of the granted patents between them. We dug into what each is actually claiming, why one nonprofit running an FDA-vouchered trial holds zero patents on purpose, and how Compass survived a million-dollar legal challenge to keep its patents alive. Read the full breakdown here.
The Times ran a broad explainer on treatment-resistant depression — roughly defined as not improving by half after two different antidepressants, which describes an estimated 31% of people treated for depression in the US. Yale's Gerard Sanacora and UC Davis's Debra Kahn walk through what's tried next: TMS (patients on TMS plus an antidepressant were 2.8x as likely to reach remission as sham TMS plus antidepressant, per a 2023 meta-analysis of 19 trials), esketamine/Spravato (52.5% response vs. about 31% on placebo in its approval trial), lithium, and combination approaches. Psilocybin, ibogaine, and 5-MeO-DMT get one line — "also being studied" — which is a useful reminder of where psychedelics actually sit in mainstream medical coverage right now: a footnote to ketamine and neuromodulation, not yet a headline treatment.
Monash University's Turner Institute gave 62 healthy adults psilocybin under four different conditions — resting, meditating, listening to music, watching a film — while scanning their brains, the largest single-site imaging study yet of psilocybin's acute effects. Brain networks that normally keep "inner world" and "outer world" processing distinct blurred together under the drug, but the specific shape of that blurring tracked whatever the person was actually doing at the time, and stronger reorganization correlated with more positive, less isolating experiences. It's healthy volunteers, not a depression trial, but it's a real mechanistic case for something clinicians already suspected: the setting during a session isn't incidental to psilocybin therapy, it's part of how the therapy works.
We missed this one when it published back on July 9 — bubbling it up now because it's a real step, not just a bill filing. State Rep. Marjorie Decker's five-year pilot program cleared the Massachusetts House, folded into a $561 million economic development bill: up to three DPH-licensed mental health clinics would be allowed to administer psilocybin or ibogaine on-site under medical supervision for PTSD, addiction, and depression, with cannabis companies, pharmaceutical companies, and psychedelic-molecule developers explicitly barred from holding a license. It still needs Senate approval and Governor Healey's signature, so it isn't law — and it's notably narrower than the broader legalization ballot measure Massachusetts voters rejected in 2024, built instead around licensed clinics rather than open access.
A Harvard team led by Paola Arlotta, with lead authors Irene Faravelli and Noelia Antón-Bolaños, sustained lab-grown human brain organoids for more than five years — three times the previous 694-day record set by UCLA and Stanford researchers in 2021. Each organoid grew past a million cerebral cortex cells and appears to retain a molecular record of its own developmental age: when the team combined older and younger cells in one organoid, the older cells jumped ahead and produced the more mature neuron types they were developmentally due to make months before the younger cells reached the same point, apparently through DNA methylation acting as an internal clock. It's a real answer to a practical problem — organoids have generally died before diseases like Alzheimer's have time to develop in them — more than it's progress toward "organoid intelligence," whatever else gets written about it elsewhere.
STAT's Elaine Chen flagged this back in August, and it's worth a closer look than a paywalled newsletter item allows: the first full results from Oregon's legal psilocybin services program, published in JAMA Network Open — the largest real-world dataset on legal psilocybin use that exists anywhere. Oregon Health & Science University tracked 346 people across 24 licensed service centers from November 2024 through June 2026, following each person for three months after a single session. The numbers are genuinely strong: moderate- to-severe depression symptoms fell from 42.2% of participants at baseline to 16.5% at three months; anxiety fell from 45.1% to 13.2%; PTSD symptoms fell from 48% to 16.8%. 91.5% of participants said they benefited, and 64.9% ranked the session among the ten most meaningful experiences of their life.
The safety side is exactly why Chen's "close monitoring" framing holds up: facilitators or clients reported a serious behavioral reaction in 4 of 346 sessions (1.2%), including one hospital transport, and no serious physical health events. That's a real, if small, adverse event rate in a context with none of the screening infrastructure a clinical trial would require — Oregon's centers do their own intake screening, but this is observational real-world data, not a controlled study. Worth reading next to our own trial tracker, which covers the controlled, pre-approval side of the same compound.
The University of Miami handed its original 1994 ibogaine Investigational New Drug application over to HHS Secretary Robert F. Kennedy Jr., which President Trump framed as accelerating ibogaine's path toward federal research and, eventually, veteran access. An IND is the foundational filing that lets researchers legally study a drug in humans — a three-decade-old one on file could shortcut groundwork any new ibogaine program would otherwise have to redo from scratch. It's the latest follow-through on Trump's April executive order directing $50 million toward psychedelic research: the VA now runs more than 20 active psychedelic-related studies, and VA and HHS signed a cooperation MOU on this exact area back in July. Ibogaine itself remains Schedule I and unapproved for any use.
Researchers from Bendable Therapy, Osmind, and UCSF — including psychedelic-neuroscience researcher Robin Carhart-Harris — tracked 88 people who went through Oregon's state-licensed psilocybin services between March 2024 and April 2025, outside any clinical trial. Depression, anxiety, and well-being all improved significantly 30 days after a session, holding up even among the nearly half of participants already taking psychiatric medication. Two people reported lingering visual aftereffects a day out that had resolved by 30 days; three reported psychological aftereffects at 30 days. It's naturalistic, with no control group and a small, self-selected sample — nearly half the participants traveled in from out of state — so it's not a substitute for a randomized trial, but it's an early read on whether Oregon's legal program is producing outcomes anywhere near what's shown up in clinical settings.
We pulled every patent we could find across seven compounds — psilocybin, MDMA, LSD, ketamine, ibogaine, DMT, and 5-MeO-DMT — and mapped who's filing, what they're claiming to treat, and where the FDA has already said no. Read the full breakdown here, or dig into the company-by-company data yourself on Altitude Intelligence.
MindMed renamed itself Definium Therapeutics, Inc. (NASDAQ: DFTX) in January, and its LSD compound went from MM120 to DT120 in the same move. This week, the company reported positive Phase 3 results from Voyage, its lead trial for generalized anxiety disorder — meeting the primary endpoint with a strong effect size. A second GAD trial and an already-positive depression trial are also underway. Right now, this is the most advanced LSD program in clinical development, by a wide margin.
HB26-1325 took effect this month, creating a state-run ibogaine research pilot inside Colorado's Behavioral Health Administration — up to five sites studying ibogaine for PTSD, opioid use disorder, and other conditions, building on the state's 2022 Natural Medicine Health Act. It requires mandated cardiac screening and medical oversight (ibogaine carries a real, well-documented arrhythmia risk), coordination with the FDA's IND process, and a benefit-sharing requirement with Indigenous communities historically associated with iboga. This is a research pilot, not legalization — no sites have been picked yet, and ibogaine remains Schedule I federally.
Resilient Pharmaceuticals — the company formerly known as Lykos, and before that MAPS PBC — has quietly resubmitted its New Drug Application for MDMA-assisted therapy for PTSD, roughly two years after the FDA's August 2024 rejection. No new Phase 3 trial this time: the filing reportedly leans on a small VA follow-up study, a new cardiac-safety study in healthy volunteers, and an audit of the original trial data addressing the unreported-adverse-events problem that helped sink it the first time. MAPS itself says it has no active role in the filing now. Worth flagging: Resilient hasn't confirmed the resubmission publicly — this is trade reporting citing people familiar with the filing, not a company statement. I go deeper on what this means for the wider patent and regulatory picture here.
Estonian researchers proposed a unifying mechanism for how serotonergic psychedelics work at the cellular level: 5-HT2A agonism on the apical dendrites of layer V pyramidal neurons — a specific class of cortical cells — loosens the usual boundaries around a thought or perception, letting it bleed into surrounding context more than it normally would. They're calling it "apical hypercontextualization," and the pitch is that it could explain the felt sense of interconnectedness that shows up across different psychedelics. Worth being clear about what this actually is: a theoretical framework built to organize existing findings, not a new experiment with its own data. It's a hypothesis for the field to test, not a result.
The VA just registered PIVOT, a 240-person randomized trial testing psilocybin for treatment-resistant depression in veterans, including those carrying PTSD alongside it. It hasn't started recruiting yet, and primary completion isn't expected until 2030, so this is a marker to watch, not a result. But a study this size, from the VA itself, is a signal in its own right.
PsiDeR, led by Professor James Rucker at King's College London and delivered through South London and Maudsley NHS Foundation Trust, is the UK's first publicly funded randomized trial of psilocybin therapy — funded by the NIHR, 60 patients with treatment-resistant depression, a single 25mg dose against a true placebo, with psychological support given to both arms. Published in Nature Medicine: 43% of the psilocybin group met response criteria at 3 weeks versus 3% on placebo, with 40% in remission, and both figures held at 6 weeks. The other detail worth noting: it was delivered in community NHS settings rather than a specialist research unit, which is as much a feasibility result as an efficacy one for a public health system weighing whether this could ever work outside a trial.
Quipazine is an old psychedelic that relieves depression-like symptoms in animal studies but also triggers nausea, because it activates a serotonin receptor in the gut (5-HT3) along with the one in the brain that does the therapeutic work (5-HT2A). Virginia Commonwealth University researchers redesigned the molecule into VCU-1012, engineered to hit the brain receptor selectively while leaving the gut one alone. In mice, it produced the same antidepressant- and anxiety-reducing effects as quipazine, plus more dendritic growth in the frontal cortex, without the GI symptoms. It's mice, not people, and there's no human safety or dosing data yet — but it's a concrete example of designing out a psychedelic's side effect without designing out the mechanism that makes it work.
Twelve veterans with severe, treatment-resistant PTSD went through psilocybin-assisted therapy in an Ohio State-led pilot. A month later, nine of them — 75% — were in remission, PTSD scores dropped by an average of 27.5 points, and there were no serious adverse events. It's tiny and open-label, with no placebo arm, so treat it as encouraging, not proof. And to be clear: this isn't the same study as PIVOT above — different sponsor, different size, different primary target.
Cybin rebranded to Helus Pharma Inc. (NASDAQ: HELP) in January, moved its US listing to Nasdaq, and renamed its lead compound from CYB003 to HLP003 — same deuterated psilocin, new name. The company just finished enrolling its pivotal Phase 3 trial, APPROACH, ahead of schedule: 223 participants testing HLP003 as an add-on to standard antidepressants for major depressive disorder. Topline data is expected by year-end.
UC San Diego has an open trial giving psilocybin-assisted therapy to its own physicians dealing with burnout, tracking outcomes on the Stanford Professional Fulfillment Index. It's Phase 1/2, feasibility-and-safety stage, not proof the treatment works for burnout specifically. But it's a notable shift in who's being studied — not just depression or PTSD patients, but the clinicians treating them.
The FDA confirmed a public hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," for September 14, 2026, gathering input on therapeutic use in supervised settings. The announcement itself is from mid-July, but it's news to us and the deadline to request to present is genuinely urgent: August 21, 2026, with written comments open through October 5. One more marker in a busier-than-usual year for the agency on this compound class.
Compass Pathways plc (NASDAQ: CMPS) followed its February COMP006 primary-endpoint announcement with 26-week durability data: the benefit from a single 25mg psilocybin dose largely held through six months, and patients who relapsed and got a second dose improved further — nearly 30% of early responders reached remission on retreatment. That's company-reported, ahead of peer review, about one formulation in one trial. Not a verdict on psilocybin generally.
A new Stanford trial, SPACE, will give psilocybin to people under general anesthesia — masking the subjective experience entirely — while tracking brain activity on EEG. It's small, ten participants, and hasn't started recruiting. But it's aimed at the field's open question: how much of psilocybin's effect depends on the trip itself, versus what's happening in the brain underneath it.
A Phase 2a trial of GH Research's GH001 — inhaled, synthetic 5-MeO-DMT (mebufotenin) — published in The Journal of Clinical Psychiatry (Vol. 87, Issue 3), reported that all 10 women enrolled with peripartum-onset major depressive disorder achieved remission by day 8, first observed just two hours after their final dose. Average MADRS score fell from 36.7 at baseline to a 35.4-point reduction by day 8 (P < .0001). No serious adverse events were reported; headache was the most common side effect, and the company reported no treatment-emergent suicidal ideation.
The design matters as much as the result: open-label, single-arm, 10 patients, no control group — exactly the kind of early signal that looks dramatic and needs a much larger, placebo-controlled trial to hold up. GH Research hasn't announced a postpartum-specific Phase 3; its confirmed pivotal program is for treatment-resistant depression, where GH001 already posted stronger-powered Phase 2b data. Worth noting: Reunion Neuroscience is running a separate, better-funded postpartum depression program (luvesilocin) on a different compound entirely — two companies chasing the same indication with unrelated molecules, tracked side by side on our trials page.
Reporting from ICPR 2026 (the Interdisciplinary Conference on Psychedelic Research) in Haarlem, Netherlands, Lucid News' Floris Wolswijk — who also runs the analytics firm Blossom and spoke on a conference panel about whether European health systems can actually afford psychedelic treatment once it's approved — lays out the gap most US coverage skips: approval is not the same as access. Several European countries have research-grade or early-access frameworks for psychedelics already (our own legal status directory tracks Switzerland's and the Netherlands' specifically), but getting a drug approved doesn't automatically mean a national health system will pay for it, and Europe's fragmented, country-by-country reimbursement systems make that a much harder problem than it is in a single-payer-adjacent US private insurance model.
It's a useful corrective to the US-centric framing most psychedelic coverage defaults to — the next real bottleneck in Europe isn't regulatory, it's financial, and nobody's solved it yet.
A new UCSF study gave 28 healthy volunteers — no depression, no prior psychedelic experience — a single 25mg dose of psilocybin and tracked their brains for a month after. EEG showed a spike in signal entropy within hours, and structural scans still showed changes a month out, with the biggest short-term entropy spikes predicting the most reported insight and well-being later. Worth naming plainly: this is healthy volunteers, not a depression trial — durable brain change correlating with subjective benefit, not proof of a clinical effect.
UNC's psilocybin-assisted therapy pilot for treatment-resistant depression has finished enrolling its 20 participants and completed its main treatment phase, with full data collection expected by March 2027. It's a small pilot, not a Phase 3 trial. But it's one more sign this kind of institutional research is now running everywhere at once — the VA, Stanford, and UNC, all in parallel.
Kevin Ryan's AlleyCorp helped found Transcend Therapeutics in 2021 to develop methylone — an MDMA analog — for PTSD. In March, Otsuka Holdings (TSE: 4578) agreed to buy it for $700 million upfront plus up to $525 million in milestones, a deal that closed in June. TSND-201, Transcend's lead compound, is the same one that picked up an FDA National Priority Voucher back in April — the fast-track program I wrote about here. It's Otsuka's second psychedelic-adjacent bet in three years, after its 2023 acquisition of Mindset Pharma.
Mice put through weeks of unpredictable stress lost interest in sugar water — a standard proxy for anhedonia — and got worse at maze tasks. A single dose of DMT reversed both, and the researchers traced it to new neuron growth in the hippocampus. It's mice, not people, and a sugar-water test isn't the same as a life. But it's one more data point that psychedelics may work partly by regrowing brain cells, not just adjusting mood chemically.
Cortical Labs' CL1 — 200,000 living human neurons grown on a microelectrode array — learned to play Doom earlier this year. In March, the company wired the neurons into a large language model so the cells' firing patterns help select the model's output. It's an early, strange proof of concept for hybrid biological-digital computing, not a sentient chip. But it's real, and it's moving fast.
Oxford researchers gave mice 5-MeO-DMT and found something odd: the animals stayed behaviorally active, with dilated pupils and normal muscle tone, while their brains showed the slow-wave activity you'd expect from sleep — a dissociated state that doesn't fit neatly into "awake" or "asleep." It's mice, not the felt experience of a Bufo session, but it's a real physiological signature for what the compound does to a brain in real time.
GH Research PLC's (NASDAQ: GHRS) GH001 — inhaled, synthetic 5-MeO-DMT — posted some of the strongest Phase 2b data in the field for treatment-resistant depression: 57.5% of patients in remission within a week, 73% still in remission at six months. In January, the FDA lifted a clinical hold on the drug's IND, clearing the way for a global Phase 3 program. As of now, the company hasn't confirmed the trial has actually started enrolling.
As brain organoids get more sophisticated, a new AJOB Neuroscience paper takes on a question that's about to matter more: when an organoid learns a task, is that intelligence, or is it something closer to felt experience? The paper argues those are different questions with different ethical stakes, and that electrical complexity or learning behavior alone doesn't settle either one. Worth watching as the organoid-AI field moves faster than the ethics conversation around it.
MindBio Therapeutics Corp.'s (CSE: MBIO) take-home, self-titrated microdose LSD looked strong in an open-label Phase 2a study — a 65% symptom reduction. But the controlled Phase 2b, 89 patients tested against an active placebo at the University of Auckland, didn't separate from placebo at all. Worth sitting with: open-label results are the least reliable kind, and a real control arm is where a lot of psychedelic optimism goes to get tested.
Germany's federal drug regulator, BfArM, approved what's reportedly the EU's first compassionate-use program for psilocybin in treatment-resistant depression — inpatient-only, at two sites in Mannheim and Berlin, using a botanical psilocybin candidate alongside psychotherapy. Capacity is small, roughly 50 patients in the first year, and compassionate use isn't approval — it's a narrow, case-by-case pathway for patients who've exhausted other options. Still, it's a real crack in the EU's otherwise cautious regulatory posture.
Beckley Psytech's Phase IIa data on BPL-003 — intranasal synthetic 5-MeO-DMT — showed a 55% response rate the day after dosing, sustained through day 85, in patients still taking an SSRI. That's notable because SSRIs are known to blunt psychedelics by downregulating the exact receptor they work through — I wrote about that interaction here on Altitude — so a signal this strong on top of one is worth watching. Side effects were mild: nasal discomfort, nausea, headache, no serious adverse events.
A placebo-controlled Phase 1 trial gave 36 adults with depression or anxiety weekly sublingual microdoses of 5-MeO-DMT — 6, 9, or 12mg — for four weeks. No serious adverse events, no organ toxicity, and no one reported an actual psychedelic effect at these doses. It's a safety study, not an efficacy one, but it's the groundwork any microdosing claim about this compound needs before it means anything clinically.
